1.
J Pediatric Infect Dis Soc
; 12(4): 242-245, 2023 Apr 28.
Article
in English
| MEDLINE | ID: covidwho-2286626
ABSTRACT
This retrospective analysis describes the administration of sotrovimab in 32 children (22 aged 12-16 years old; 10 aged 1-11 years old) who were at high risk of deterioration to severe COVID-19 disease. We provide dosing suggestions and demonstrate the feasibility of sotrovimab use in the younger pediatric population (<12 years old and <40 kg).
Subject(s)
COVID-19 , Humans , Child , Adolescent , Infant , Child, Preschool , Retrospective Studies , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Neutralizing
2.
Aust Prescr
; 45(2): 67-68, 2022 Apr.
Article
in English
| MEDLINE | ID: covidwho-1811734